LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq: AKTX) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at email@example.com.
On April 26, 2017, Edison Research Ltd. issued a report on Akari called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced the report had been withdraw due to “material inaccuracies.” On May 11, 2017, the Company announced that Chief Executive Officer Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives had any involvement with the materially inaccurate research report.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.